ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)

Stock News08:20

ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174217966?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174217966","market":"sg","top_or_hot":-1,"title":"ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)","media":"Stock News","content":"<p>ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-06 08:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1174217966","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174217966","pubTimestamp":1778026854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","LU0997586861.USD":"FIDELITY NORDIC \"A\" (USDHDG) ACC","BK1161":"生物科技","BK1574":"生物医药B类股","ECO":"Okeanis Eco Tankers","01672":"歌礼制药-B","BK4144":"石油与天然气的储存和运输","01477":"欧康维视生物-B"},"translate_title":"歌礼-B(01672)将在第33届欧洲肥胖大会(ECO 2026)上展示多个项目数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"ECO":1,"01672":1},"content_text":"ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174217966","isCrawlerRequest":true}